Goldstein, D., Spry, N., Shapiro, J., Porter, I. W. T., Hruby, G., Horvath, L., Bydder, S., Underhill, C., Harvey, J., Gebski, V. J., , Cummins, M. M., Brown, C., van Hazel, G. A., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S. P., Wratten, C.. Nature Publishing Group; 2012. The GOFURTGO study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

de Bock, C. E., Garg, M. B., Scott, N., Sakoff, J. A., Scorgie, F. E., Ackland, S. P., Lincz, L. F.. Nature Publishing Group; 2010. Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.

Barbour, A. P., Walpole, E. T., Mai, G. T., Barnes, E. H., Watson, D. I., Ackland, S. P., Martin, J. M., Burge, M., Finch, R., Karapetis, C. S., Shannon, J., Nott, L. M., Varma, S., Marx, G., Falk, G. L., Gebski, V., Oostendorp, M., Wilson, K., Thomas, J., Lampe, G., , , , , , , , . Elsevier; 2020. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.

Folprecht, G., Pericay, C., Ackland, S. P., Swinson, D., Kopp, M., Udovitsa, D., Hall, M., Iveson, T., Vogel, A., Zalcberg, J. R., Saunders, M. P., Thomas, A., Lopez Lopez, R., Roh, J. K., Chistyakov, V., Höhler, T., Kim, J. - S., Hofheinz, R. D.. Oxford University Press; 2016. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.

Garg, M. B., Lincz, L. F., Adler, K., Scorgie, F. E., Ackland, S. P., Sakoff, J. A.. Nature Publishing Group; 2012. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis.